Thursday, 19 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 19 March 2026
News

Global high-flyer lands Aussie gig

Posted 19 March 2026 AM

After a long career in Big Pharma, seasoned licensing executive Nilesh Wadhwa has been snapped up by ASX-listed Firebrick Pharma, tasked with driving approvals and sales of its Nasodine product range.

Following an independent international search, the Melbourne-based company named Wadhwa as Head of Business Development and Licensing, a new role created to drive the number of markets where Nasodine is approved and/or sold from three countries to up to 10 countries over the next three years.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.